MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Levodopa(L-dopa)"

  • 2022 International Congress

    Effects of Parkinson’s disease and freezing of gait on the kinematic and kinetic gait parameters

    D. Campos, T. Shida, C. Oliveira, R. Treza, S. Hondo, E. Los Angeles, C. Bernardo, L. Oliveira, M. Carvalho, D. Coelho (São Bernardo Campos, Brazil)

    Objective: This study aims to evaluate the effects of Parkinson's disease and freezing of gait (FoG) on the kinematic and kinetic gait parameters, both in…
  • 2022 International Congress

    Bitopertin, a GlyT1 inhibitor, attenuates the development of dyskinesia in the 6-OHDA-lesioned rat

    I. Frouni, W. Kang, D. Bédard, S. Belliveau, C. Kwan, A. Hamadjida, P. Huot (Montreal, Canada)

    Objective: To evaluate the effect of the glycine transporter 1 (GlyT1) inhibitor bitopertin at preventing dyskinesia development in the 6-hydroxydopamine (6-OHDA)-lesioned rat model of Parkinson’s…
  • 2022 International Congress

    Lateral shifting from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in the treatment of advanced idiopathic Parkinson’s disease (PD): Case series

    M. Abu Al-Melh, M. Farghal, N. Abdelall (Ahmadi governorate, Kuwait)

    Objective: To report our experience with transitioning from apomorphine subcutaneous infusion (ASI) to levodopa-carbidopa intestinal gel (LCIG) in two patients with advanced idiopathic Parkinson’s disease (PD). Background: Device-assisted…
  • 2022 International Congress

    Amelioration of Levodopa-induced Dyskinesias using Genetic Silencing of Striatal CaV1.3 in Parkinsonian Rats: Impact of Sex and Advancing Age

    M. Caulfield, F. Manfredsson, J. Stancati, C. Sortwell, S. Boezwinkle, M. Vanderwerp, T. Collier, K. Collier (Grand Rapids, USA)

    Objective: To advance understanding of striatal CaV1.3 (cacna1d) channel silencing as a therapeutic approach to reduce levodopa-induced dyskinesias (LID), a side effect of long-term escalating…
  • 2022 International Congress

    The effect of levodopa on speech in patients with Parkinson’s disease

    M. Mrackova, R. Marecek, J. Mekyska, M. Kostalova, R. Rektorova (Brno, Czech Republic)

    Objective: To assess levodopa-induced changes in fMRI signal in areas involved in speech production (ROIs) in PD. Evaluate association between these changes and changes in…
  • 2022 International Congress

    Patient and caregiver satisfaction of video-assisted telenursing in patients treated with LCIG

    T. Gurevich, A. Evans, G. Kägi, D. Koziorowksi, L. Bergmann, JC. Parra Riaza, O. Sanchez-Soliño, J. Slawek (Tel Aviv, Israel)

    Objective: To evaluate the feasibility and patient satisfaction of video-assisted telenursing as well as demonstrate resolution for treatment-related issues in the real-word levodopa-carbidopa intestinal gel…
  • 2022 International Congress

    Natural progression of patients with Parkinson disease on less pulsatile levodopa therapy

    M. Lin, R. Laureno, A. Lenka (Washington, USA)

    Objective: To evaluate the natural progression of Parkinson disease (PD) in patients on less pulsatile levodopa therapy (LPT). Background: Previously we have shown that patients…
  • 2022 International Congress

    Comparing duodenal levodopa infusion based on length of treatment in advanced Parkinson’s.

    J. Alonso Maroto, E. Casas Peña, I. Muro García, M. Domínguez Gallego, E. Valiente Gordillo, L. López Manzanares, JA. Vivancos Mora (Madrid, Spain)

    Objective: In this study we seek to compare characteristics and complications of patients suffering from advanced Parkinson's treated with duodenal levodopa infusion. Background: Motor fluctuations…
  • 2022 International Congress

    Heart rate variability is affected by standing and medication intake in Parkinson’s disease

    F. Cucinotta, F. Morgante, I. Cociasu, E. Pereira, E. Makovac, L. Ricciardi (London, United Kingdom)

    Objective: To evaluate the effect of levodopa and orthostatism on heart rate variability (HRV) in a sample of consecutive subjects with Parkinson's disease (PD). Background:…
  • 2022 International Congress

    Globus pallidus as a neurosurgical target in the management of levodopa-induced dyskinesias

    A. Simonyan, V. Tyurnikov, V. Poleshuk, A. Simonyan, A. Gushcha (Moscow, Russian Federation)

    Objective: Parkinson's disease (PD) is a neurodegenerative disorder characterized by the development of motor symptoms, as well as some non-motor changes. Symptomatic treatment of PD…
  • « Previous Page
  • 1
  • …
  • 20
  • 21
  • 22
  • 23
  • 24
  • …
  • 62
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley